^
    Back
    Association details:
    Biomarker:PGP expression
    Cancer:Osteosarcoma
    Drug:Mepact (mifamurtide) (Macrophage stimulant, Monocyte stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2)

    Published date:
    02/24/2022
    Excerpt:
    For Pgp+ patients, 5-year EFS after definitive surgery (null hypothesis, 40%) was 69.8% (90% confidence interval [CI], 62.2%-76.2%): 59.8% in PRs and 83.7% in GRs. adjuvant mifamurtide, combined with HDIFO for a poor response to induction chemotherapy, could improve EFS in Pgp+ patients.
    Secondary therapy:
    ifosfamide
    DOI:
    10.1002/cncr.34131